Key points are not available for this paper at this time.
Design
Review
Reviews Pak1 signaling across cardiac conditions; leaves open its viability as a therapeutic target pending clinical trials.
This article is part of a themed section on Spotlight on Small Molecules in Cardiovascular Diseases. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.8/issuetoc.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: